1832 Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.19M | Buy |
+9,498
| New | +$1.19M | ﹤0.01% | 541 |
|
|
2024
Q3 | – | Sell |
-541,200
| Closed | -$74.5M | – | 810 |
|
|
2024
Q2 | $74.5M | Buy |
541,200
+504,400
| +1,371% | +$69.4M | 0.06% | 152 |
|
|
2024
Q1 | $5.08M | Sell |
36,800
-4,200
| -10% | -$579K | ﹤0.01% | 372 |
|
|
2023
Q4 | $5.4M | Buy |
+41,000
| New | +$5.4M | 0.01% | 375 |
|
|
2023
Q1 | – | Sell |
-691,400
| Closed | -$82.6M | – | 942 |
|
|
2022
Q4 | $82.6M | Buy |
691,400
+216,500
| +46% | +$25.9M | 0.14% | 130 |
|
|
2022
Q3 | $50.4M | Buy |
474,900
+397,500
| +514% | +$42.2M | 0.09% | 182 |
|
|
2022
Q2 | $7.55M | Buy |
+77,400
| New | +$7.55M | 0.01% | 372 |
|
|
2020
Q3 | – | Sell |
-205,600
| Closed | -$25.5M | – | 715 |
|
|
2020
Q2 | $25.5M | Sell |
205,600
-350,700
| -63% | -$43.6M | 0.08% | 171 |
|
|
2020
Q1 | $49.9M | Sell |
556,300
-81,600
| -13% | -$7.32M | 0.18% | 115 |
|
|
2019
Q4 | $67.3M | Buy |
637,900
+107,800
| +20% | +$11.4M | 0.2% | 103 |
|
|
2019
Q3 | $46.8M | Buy |
+530,100
| New | +$46.8M | 0.15% | 128 |
|
|
2018
Q4 | – | Sell |
-658,700
| Closed | -$79.2M | – | 695 |
|
|
2018
Q3 | $79.2M | Buy |
658,700
+271,300
| +70% | +$32.6M | 0.26% | 92 |
|
|
2018
Q2 | $37M | Buy |
+387,400
| New | +$37M | 0.13% | 140 |
|
|
2018
Q1 | – | Sell |
-63,700
| Closed | -$4.92M | – | 720 |
|
|
2017
Q4 | $4.92M | Buy |
+63,700
| New | +$4.92M | 0.02% | 292 |
|